- Home
- ROIV vs AVB Comparison
ROIV vs AVB Comparison
Compare ROIV & AVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | AVB |
|---|---|---|
| Founded | 2014 | 1978 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 22.5B |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ROIV | AVB |
|---|---|---|
| Price | $29.24 | $172.67 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 15 |
| Target Price | $28.94 | ★ $198.20 |
| AVG Volume (30 Days) | ★ 4.2M | 837.0K |
| Earning Date | 05-28-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 4.04% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 7.40 |
| Revenue | $29,053,000.00 | ★ $3,040,725,000.00 |
| Revenue This Year | N/A | $4.04 |
| Revenue Next Year | $744.61 | $5.03 |
| P/E Ratio | ★ N/A | $23.79 |
| Revenue Growth | N/A | ★ 4.36 |
| 52 Week Low | $10.58 | $160.10 |
| 52 Week High | $30.33 | $213.34 |
Technical Indicators
Market Signals| Indicator | ROIV | AVB |
|---|---|---|
| Relative Strength Index (RSI) | 57.91 | 56.26 |
| Support Level | $20.46 | $167.78 |
| Resistance Level | $30.33 | $181.72 |
| Average True Range (ATR) | 0.85 | 2.90 |
| MACD | 0.10 | 1.19 |
| Stochastic Oscillator | 73.60 | 72.75 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About AVB AvalonBay Communities Inc.
AvalonBay Communities owns a portfolio of 296 apartment communities with more than 90,000 units and is developing 24 additional properties with approximately 8,600 units. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.